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Abnormal expansion or depletion of particular lymphocyte subsets is associated with clinical manifestations such as HIV progression to
AIDS and autoimmune disease. We sought to identify genetic predictors of lymphocyte levels and reasoned that these may play a role in
immune-related diseases.We tested 2.3million variants for association with ﬁve lymphocyte subsets, measured in 2538 individuals from
the general population, including CD4þ T cells, CD8þ T cells, CD56þ natural killer (NK) cells, and the derived measure CD4:CD8 ratio.
We identiﬁed two regions of strong association. The ﬁrst was located in the major histocompatibility complex (MHC), with multiple
SNPs strongly associated with CD4:CD8 ratio (rs2524054, p ¼ 2.1 3 1028). The second region was centered within a cluster of genes
from the Schlafen family and was associated with NK cell levels (rs1838149, p¼ 6.13 1014). TheMHC association with CD4:CD8 repli-
cated convincingly (p ¼ 1.43 109) in an independent panel of 988 individuals. Conditional analyses indicate that there are two major
independent quantitative trait loci (QTL) in the MHC region that regulate CD4:CD8 ratio: one is located in the class I cluster and inﬂu-
ences CD8 levels, whereas the second is located in the class II cluster and regulates CD4 levels. Jointly, both QTL explained 8% of the
variance in CD4:CD8 ratio. The class I variants are also strongly associated with durable host control of HIV, and class II variants are
associated with type-1 diabetes, suggesting that genetic variation at the MHC may predispose one to immune-related diseases partly
through disregulation of T cell homeostasis.The immune system’s ability to eliminate cancer cells,
bacteria, and viruses while avoiding self-harm is critical
for survival and requires a dynamic regulation of lympho-
cyte numbers. Disruption of the regulatory mechanisms
involved in lymphocyte production, sequestration, or
apoptosis can lead to abnormal expansion or depletion of
particular subsets, and this is associated with clinical
manifestations such as persistent bacterial infections,1
HIV progression to AIDS [MIM 609423],2 and autoimmune
disease.3 Because lymphocytenumbers vary amonghealthy
individuals and this variation is partly heritable,4,5 we
sought to identify genetic predictors of cell levels and
reasoned that these may play a role in immune-related
diseases.
Five lymphocyte subsets weremeasured in the peripheral
blood of 2538 adolescent twins from 1089 Australian fami-
lies ascertained fromthegeneral population; these included
CD3þ T cells, CD4þ T cells, CD8þ T cells, CD19þ B cells,
and CD56þ natural killer (NK) cells (Table S1, available
online). Twins were enlisted through primary schools,
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days in the context of an ongoing study of melanocytic
naevi, described in detail elsewhere.6,7 The clinical protocol
used for blood collection andprocessinghas been described
in detail previously.4 In brief, venous blood samples from
the twins and, where possible, from their parents and
siblings were collected for hematological assessment (twins
and siblings only) and DNA genotyping. The lymphocyte-
subset analysis was performed on whole blood with the
AutoPrep (Coulter) and direct ﬂuorochrome-conjugated
monoclonal antibodies to CD3, CD4, CD8, CD19 and
CD56 antigens (Coulter). Analysis was performed on an
Epics 753 cytoﬂuorograph (Coulter) with the use of stan-
dardized control samples and machine settings. For each
lymphocyte subset, outlier observations (5 standard devia-
tions above the mean) at each time of assessment (ages
12, 14, and 16)were excluded fromanalysis and the average
across all available time points was computed. Blood
samples were collected between 8:00 a.m. and 5:00 p.m.,
but there were no signiﬁcant effects of time of collection
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Table 1. Regions of Strongest Association with Variation in Lymphocyte Numbers
Locus Trait SNP, Allele Panel N Allele Frequency Effecta SE h2 (%) Association p Value
6p21 CD4:CD8 rs2524054, A GWASb 2495 0.32 0.37 0.03 5.7 2.1 3 1028
Replication 959 0.28 0.30 0.05 4.0 1.4 3 109
6p21 CD8 rs2524054, A GWAS 2497 0.32 0.31 0.03 4.1 6.2 3 1021
Replication 881 0.28 0.35 0.06 4.9 4.3 3 109
17q12 NK cells rs1838149, A GWAS 2474 0.42 0.24 0.03 2.8 6.1 3 1014
Replication 584 0.36 0.08 0.07 0.3 0.240
6p21 CD4 rs9271366, G GWAS 2498 0.18 0.25 0.04 1.8 1.9 3 109
Replication 969 0.16 0.10 0.07 0.2 0.168
Abbreviations are as follows: Freq, allele frequency; SE, standard error of the beta estimate; h2, percentage of phenotypic variance explained by the SNP; NK,
natural killer.
a Effect corresponds to standard deviation units for the transformed phenotype.
b The GWAS panel included 2538 genotyped and phenotyped siblings from 1089 Australian families; genotype data from 1457 parents who were not pheno-
typed were also included in the analysis.the derived measure CD4:CD8 ratio, which has prognostic
utility for diseases such as HIV2 and cancer.8 Traits were
adjusted for age and sex effects (if signiﬁcant) and normal-
ized with an inverse-normal transformation. Trait heri-
tabilities ranged from 76% to 85%, with low to moderate
cross-trait phenotypic correlations (Table S2).
Genotyping was performed with the Illumina 610-
Quad BeadChip, 529,721 SNPs passing quality control
(Table S3). Genomic coverage was extended to 2.3 million
SNPs with the use of data from the CEU HapMap samples
andMACH (seeWeb Resources). In brief, we ﬁrst compared
data from a set of 350 randomly chosen individuals with
the phased haplotype data from the CEU HapMap samples
(phase IþII, release 22, build 36) to generate recombination
and error maps. We then used these to impute autosomal
HapMap SNPs in groups of ten individuals to speed up the
computation by using the same reference panel. After
imputation, data were available for 2.5 million SNPs. Of
these, we dropped SNPs with an imputation score < 0.3
(indicating low imputation conﬁdence; ~3%), a minor
allele frequency (MAF)<0.01, or aHardy-Weinberg equilib-
rium score of p < 106 (~5%), resulting in a data set with
2,354,458 SNPs available for analysis. Simulations showed
that this data set provided 80% power for detection of a
quantitative trait locus (QTL) that explained ~2% of the
phenotypic variance (Figure S1). This study was performed
with the approval of the appropriate ethics committee and
the informed written consent of all participants.
Individual SNPs were tested for association with the
family-based SCORE test implemented in Merlin.9 Similar
results were obtained for our top regions of association
with the more computationally intensive variance-compo-
nents likelihood-ratio test, which accounts for identity-by-
descent sharing when modeling the correlation between
relatives (not shown). For imputed SNPs, we analyzed
best-guess genotypes; on the basis of a leave-one-out
procedure, we estimated that the concordance between
our best guess and the actual observed genotypes wasThe Ahigh, ranging from97% (MAF> 0.25) to 99% (MAF< 0.05).
Furthermore, the genomic inﬂation factor was close to
1.00 for all traits (Figure S2), indicating that the analysis
of best-guess genotypes instead of allelic dosage had anegli-
gible impact on the results, as did other potential technical
artifacts.
Genome-wide association study (GWAS) results are
shown in Figure S3 and are available for download (see
Web Resources). Two regions exceeded our threshold for
signiﬁcance of p ¼ 8.3 3 109 (Table 1), which was
Bonferroni adjusted to account for the six traits tested
(5 3 108 / 6). The ﬁrst region was located in the major
histocompatibility complex (MHC), with multiple SNPs
strongly associated with CD4:CD8 ratio, CD8 levels, and
CD4 levels (Figure S4). The most notable results were for
rs2524054, an imputed SNP located in the MHC class I
gene cluster that inﬂuenced CD4:CD8 ratio (p ¼ 2.1 3
1028) and CD8 levels (p¼ 6.23 1021). The second region
of strongest association was for NK cell levels on chromo-
some 17q12 (rs1838149, imputed, p ¼ 6.1 3 1014)
(Figure S5), centered within a cluster of genes from the
Schlafen family that regulate thymocyte development.10
We ﬁrst sought to conﬁrm these associations in an inde-
pendent group of 988 individuals from 550 families also
ascertained from the general population (Table S1). This
replication data set was composed of two independent
panels. The ﬁrst panel comprised 592 siblings and 386 of
their parents (genotypes only) from 272 Australian families
also ascertained and tested as part of the melanocytic naevi
study described above but not included in the GWAS
panel. Genotyping was performed with the Sequenom
MassARRAY system; all SNPs had < 5% missing data,
a Hardy-Weinberg equilibrium p value > 0.01, and no
Mendelian errors. The second panel consisted of 396
siblings from 278 families from the UK, ascertained as
part of the TwinsUK study. This is a large cohort of British
twins historically developed for the study of the herita-
bility and genetics of diseases with a higher prevalencemerican Journal of Human Genetics 86, 88–92, January 8, 2010 89
Figure 1. Association Analysis of MHC
Variants and CD4:CD8 Ratio
Results are shown (A) before and after
conditioning on (B) HLA-B and (C) both
HLA-B and HLA-DRB1 peak variants. The
proportion of phenotypic variance ex-
plained (h2) is shown for the most-associ-
ated SNP in each panel. Horizontal line
indicates a p value of 8.3 3 109. SNPs
with a p value < 1 3 105 are highlighted
in green.among women.11 The sample is not enriched for any
particular disease or trait and is representative of the British
general population.12 The clinical protocol used for blood
collection and processing has been described in detail else-
where5,13 and was equivalent to that used for the Austra-
lian samples. NK cells were not measured in this panel.
Genotyping was performed with the Illumina 317K or
610-Quad assays. The rs9271366 variant was not available
and was therefore imputed with high conﬁdence (imputa-
tion score ¼ 0.98) via IMPUTE.14 Ethics approval for this
study was obtained from the Guy’s and St. Thomas’
Hospital Ethics Committee, and written informed consent
was obtained from every participant.
In the replication group, a consistent, strong association
was observed for the MHC class I variant rs2524054 with
both CD4:CD8 ratio (p ¼ 1.4 3 109) and CD8 levels
(p ¼ 4.3 3 109), conﬁrming that genetic variation in90 The American Journal of Human Genetics 86, 88–92, January 8, 2010the MHC is a major determinant of
CD8 counts and CD4:CD8 ratio in
the population (Table 1). There was
no evidence for heterogeneity of
effects for rs2524054 between the
two replication subgroups (p ¼ 0.25).
Consistent but weaker effects were
also observed between the 17q12
variant rs1838149 and NK cell levels,
as well as between the MHC class II
variant rs9271366 and CD4 levels,
although these were not signiﬁcant
(p ¼ 0.24 and p ¼ 0.17, respectively).
Larger replication cohorts are re-
quired to unambiguously conﬁrm
these two putative associations. Of
note, we also tested for replication
the GWAS variant with the strongest
association with NK levels among the
genotyped (i.e., not imputed) SNPs
in the 17q12 region (rs9916629-C,
effect ¼ 0.22, p ¼ 4.7 3 1011). We
observed a consistent and signiﬁcant
association in the replication group
for this variant (effect ¼ 0.18,
p ¼ 0.012), suggesting that this locus
is indeed likely to be a true-positive
ﬁnding.Notable loci (p < 106) that did not meet our threshold
for genome-wide signiﬁcance included chromosome 4p16
(Figure S6A), which is associated with CD4:CD8 ratio
(rs12644662-C, effect ¼ 0.218, p ¼ 1.5 3 108; closest
genes ZFYVE28 and RNF4 [MIM 602850]), and chromo-
some 12q24 (Figure S6B), with the T allele of rs3184504
associated with increased CD4 levels (effect ¼ 0.159,
p ¼ 6.2 3 107). The latter results are consistent with the
established association between this nonsynonymous
SNP in SH2B3 (MIM 605093) and all major human blood
cell types.15
Given the broad association observed between the MHC
and CD4:CD8 ratio (Figure S4), we then investigated
whether the results were consistent with a single or
multiple independent QTL in this region. The strongest
association was for rs2524054 in HLA-B (MIM 142830)
(Figure 1A), a locus that explained 5.7% of the variance
of CD4:CD8 through the regulation of CD8 but not CD4
levels (Table S4).
After conditioning on this MHC class I signal, there was
evidence for a secondary peak for CD4:CD8 ratio in the
MHC class II gene cluster, explaining 2.4% of the trait vari-
ance (Figure 1B). The most strongly associated variant was
now rs9270986 (p¼ 4.43 1012), which was located 16 kb
upstream of the HLA-DRB gene complex and inﬂuenced
CD4 but not CD8 levels (Table S4). We also tested this
variant for association in the replication panel and
observed a signiﬁcant, consistent effect (p ¼ 1.1 3 104,
3.1% of the CD4:CD8 variance explained). When the asso-
ciations in HLA-B and HLA-DRB were accounted for, there
were three residual independent association peaks near the
MICA (MIM 600169) (rs2523471, p ¼ 1.5 3 107), HLA-A
(MIM 142800) (rs2523946, p ¼ 1.4 3 107), and HLA-DP
genes (rs1431403, p ¼ 9.1 3 107) (Figure 1C), each ex-
plaining 1.2%–1.4% of the variation in CD4:CD8 ratio
(Table S4). No variant explained > 1% of the CD4:CD8
variance after the top HLA-B, HLA-DRB, MICA, HLA-A,
and HLA-DP variants were accounted for.
Taken together, our results indicate that there are two
major independent QTL in the MHC region that regulate
CD4:CD8 ratio in the general population. One is located
in the class I cluster and accounts for 4.1% of the pheno-
typic variance of CD8 in our sample. Given that the most-
associated variant in this region correlated with both
HLA-B and CCHR1 gene expression16 (Table S5), either of
these genes is a likely causal candidate. The second QTL
is located in the MHC class II cluster and regulates CD4
levels. Gene expression results16 point to HLA-DRB1 (MIM
142857), HLA-DQB1 (MIM 604305), or HLA-DQA1 (MIM
146880) as likely candidates for this association (Table S5).
Jointly, the additive effects of both QTL explain 8% of the
variance in CD4:CD8 ratio, with some evidence for domi-
nance but no signiﬁcant epistatic effects (Table S6). Addi-
tional independent variants with smaller effects may exist
in the region, as exempliﬁed by rs2523471 (MICA),
rs2523946 (HLA-A), and rs1431403 (HLA-DP), but these
need to be studied in larger samples.
Finally, we investigated whether the two MHC variants
independently associated with CD4:CD8 ratio were also
likely to play a role in the etiology of immune-related
diseases. In the Wellcome Trust Case-Control Consortium
study (Table S7), the A allele of rs9270986 (class II) was
strongly protective against type-1 diabetes (T1D; odds ratio
[OR] ¼ 0.04, p ¼ 1.0 3 10125) and rheumatoid arthritis
(RA; OR ¼ 0.60, p ¼ 2.7 3 1015), as previously re-
ported.17,18 The same allele was associated with increased
CD4 levels in our data set and was in complete linkage
disequilibrium with HLA-DQB1*0602 (r2 ¼ 1) (Table S7),
a T1D-protective allele17 that appears to decrease CD4
T cell apoptosis.19 An association of high CD4 counts
with an MHC class II allele known to be protective for
these diseases is surprising, because predisposition to cell-
mediated autoimmune disease is held to be associated
with thymic selection of cells with higher than normalThe Aafﬁnity for MHC-peptide, a genetically determined prop-
erty of the T cells.20,21 If conﬁrmed, these results suggest
that the extent of selection of a regulatory rather than an
effector CD4 cell population may contribute to disease
risk conveyed by these alleles.
On the other hand, the A allele of rs2524054 (class I),
whichwas associatedwithdecreasedCD8 levels in our anal-
ysis, was predisposing for T1D (OR¼ 1.33, p¼ 3.33 109).
This suggests that repertoire selection in T1D may pref-
erentially favor self-reactive T cells because this MHC
allele binds self-peptide poorly, favoring both a smaller
number of surviving T cells and a higher percentage of
self-reactivity.
We also tested whether the two variants inﬂuenced
lymphocyte numbers in HIV-positive patients. A hallmark
of chronic, untreated HIV-1 infection is the gradual deple-
tion of CD4 T cells and the expansion of CD8 T cells,
resulting in a marked reduction of the CD4:CD8 ratio.
Therefore, we focused on HIV controllers (Table S8), indi-
viduals who naturally control HIV-1 viremia to extremely
low or undetectable levels without antiretroviral medica-
tions, minimizing the risk of confounding due to the effect
of persistent viremia. Neither variant showed a statistically
signiﬁcant association with CD4:CD8 ratio (Table S9), but
the A allele of rs2524054 was strongly associated with
immune control of HIV-1 viremia when the controllers
were compared to a group of HIV-1 progressors (OR¼ 0.32,
p¼ 9.13 1011) (Table S7). This result raises the interesting
possibility that genetic variants that regulate the CD4:CD8
ratio may play a role in natural control of HIV-1 viremia.
Whether the variants discovered in this study protect
one against or predispose one to HIV-1 infection is an
interesting hypothesis that could not be tested in this
patient population and warrants further investigation.
In conclusion, we provide evidence that two indepen-
dent QTL located in class I and class II MHC genes regulate
the CD4:CD8 T cell ratio in the general population. To our
knowledge, these represent the ﬁrst conﬁrmed QTL for this
trait in humans. Given that both are also associated with
risk of T1D, RA, or host control of HIV in independent
cohorts, we speculate that genetic variation at these loci
may predispose one to immune-related diseases partly
through disregulation of T cell homeostasis.Supplemental Data
Supplemental Data include six ﬁgures, nine tables, and a list of
members of the International HIV Controllers Study and can be
found with this article online at http://www.ajhg.org.Acknowledgments
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